Ben Van Baelen
Overview
Explore the profile of Ben Van Baelen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steytler J, Craig C, van der Ryst E, Van Baelen B, Nuttall J, van Niekerk N, et al.
Clin Infect Dis
. 2022 Nov;
76(6):996-1002.
PMID: 36345569
Background: The Ring Study demonstrated 35.1% human immunodeficiency virus type 1 (HIV-1) infection risk reduction among participants who used the Dapivirine vaginal ring-004 (DVR), whereas the Dapivirine Ring Extended Access...
2.
Steytler J, van der Ryst E, Craig C, Van Baelen B, Nuttall J, van Niekerk N, et al.
Clin Infect Dis
. 2022 Oct;
76(3):389-397.
PMID: 36189636
Background: Participants with human immunodeficiency virus (HIV) seroconversion in The Ring Study, a phase 3 trial of dapivirine vaginal ring (DVR), or in the open-label extension trial dapivirine ring extended...
3.
Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al.
Lancet HIV
. 2021 Feb;
8(2):e77-e86.
PMID: 33539761
Background: The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal...
4.
Roozendaal R, Hendriks J, Van Effelterre T, Spiessens B, Dekking L, Solforosi L, et al.
NPJ Vaccines
. 2020 Dec;
5(1):112.
PMID: 33335092
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of...
5.
Diacon A, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, et al.
Am J Respir Crit Care Med
. 2017 Apr;
196(12):1612-1615.
PMID: 28448721
No abstract available.
6.
Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, et al.
SAGE Open Med
. 2017 Apr;
5:2050312116686482.
PMID: 28382208
Objective: VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients. Methods: In a 48-week, phase IV, single-arm, multicenter study, patients...
7.
Diacon A, Van Baelen B, Theeuwes M
N Engl J Med
. 2016 Dec;
375(26):2609-10.
PMID: 28032964
No abstract available.
8.
Nel A, van Niekerk N, Kapiga S, Bekker L, Gama C, Gill K, et al.
N Engl J Med
. 2016 Dec;
375(22):2133-2143.
PMID: 27959766
Background: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing...
9.
Pym A, Diacon A, Tang S, Conradie F, Danilovits M, Chuchottaworn C, et al.
Eur Respir J
. 2015 Dec;
47(2):564-74.
PMID: 26647431
Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial (TMC207-C208; NCT00449644). The current phase 2, multicenter, open-label,...
10.
Kagan R, Johnson E, Siaw M, Van Baelen B, Ogden R, Platt J, et al.
AIDS Res Hum Retroviruses
. 2013 Jul;
30(2):151-9.
PMID: 23875707
Cenicriviroc is a once-daily oral CCR5/CCR2 antagonist in development for treatment of HIV infection. CVC Study 202 (652-2-202; NCT01338883) excluded treatment-naive subjects demonstrated to harbor non-R5 (CXCR4-tropic or dual-mixed) tropic...